Primary study · included by 1 review

Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: A prospective cohort study.

Chanprapaph 2021 · Chanprapaph Kumutnart, Ounsakul Vipawee, Pruettivorawongse Duangrat, et al. · Asian Pacific journal of allergy and immunology · 2021

Included by

Diagnostic Agreement in Subepidermal Blistering Diseases: Is ELISA Test Reliable as Direct Immunofluorescence? A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Non-Cochrane · DTA · 2026 · cited as Chanprapaph 2021 · Table 2; References

Outcome this study informs	Pooled effect	Evidence	Certainty
Diagnostic agreement between ELISA and DIF (risk difference in test positivity) ELISA (BP180 and/or BP230) in bullous pemphigoid (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy	RD 0.19 [0.13, 0.25]	27 studies · 2238 participants	GRADE not reported
Diagnostic agreement between ELISA and DIF (risk difference in test positivity) ELISA for BP180 autoantibodies (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy	RD 0.26 [0.19, 0.33]	35 studies · 2776 participants	GRADE not reported
Diagnostic agreement between ELISA and DIF (risk difference in test positivity) ELISA for BP230 autoantibodies (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy	RD 0.59 [0.47, 0.71]	27 studies · 2097 participants	GRADE not reported

1 including review in total.